Case Report: Atypical Presentation of Nivolumab‐Induced Immune‐Related Vasculopathy Imitating Raynaud's Phenomenon in Lung Cancer
- 24 April 2026
- journal article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (5) , e70665
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathologySeminars in Arthritis and Rheumatism, 2024
- Immune-related adverse events of immune checkpoint inhibitors: a reviewFrontiers in Immunology, 2023
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitorsAnnals of the Rheumatic Diseases, 2021
- Immune Checkpoint Inhibitors for Lung Cancer Treatment: A ReviewJournal of Clinical Medicine, 2020
- Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's-Like PhenomenonThe Oncologist, 2020
- Vasculitis associated with immune checkpoint inhibitors—a systematic reviewClinical Rheumatology, 2018
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working GroupJournal for ImmunoTherapy of Cancer, 2017